Effect of Chronic Domperidone Use on QT Interval: A Large Single Center Study
| Autor: | Ron Schey, Joshua M. Cooper, Justin Field, Zubair Malik, Melissa Wasilewski, Rajiv Bhuta, Henry P. Parkman |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Gastroparesis Single Center QT interval Electrocardiography Internal medicine medicine Humans Longitudinal Studies Dopamine receptor antagonist Retrospective Studies medicine.diagnostic_test Dose-Response Relationship Drug business.industry Gastroenterology Retrospective cohort study Middle Aged medicine.disease Domperidone Long QT Syndrome Cardiology Dopamine Antagonists Female business medicine.drug |
| Zdroj: | Journal of clinical gastroenterology. 53(9) |
| ISSN: | 1539-2031 |
| Popis: | The goal of this study was to determine the effect and safety of domperidone on QTc interval at the commonly prescribed doses of 30 to 80 mg daily.Domperidone is a dopamine receptor antagonist used for the treatment of gastroparesis. However, it has been associated with QT prolongation, ventricular arrhythmias, and sudden cardiac death.This study analyzed patients prescribed domperidone for treatment of gastroparesis between January 2012 and September 2017 at a single center. This study reviewed EKGs, primarily the QTc interval, taken at baseline, 2 to 6 months after initiation of domperidone, 6 to 12 months after initiation, and ≥12 months after initiation. Concurrent QTc prolonging medications were recorded for each patient. The primary endpoint was QTc prolongation500 ms. Secondary endpoints were QTc450 ms for males, a QTc470 ms for females, QTc prolongation ≥20 ms above baseline, and QTc prolongation60 ms above baseline.In total, 246 patients were included for analysis (age, 46.3±17.4 y; F 209). EKGs were available for all 246 patients before treatment, 170 patients at 2 to 6 months, 135 at 6 to 12 months, and 152 patients at least 1 year after domperidone initiation.Of 246 subjects, 15 patients (6.1%, 9 female) had clinically important QTc prolongation; 11 had QTc450 ms for males or470 ms for females; none had QTc prolongation500 ms; 5 (2.0%) had60 ms over baseline and 61 (24.7%) patients had QTc increase of ≥20 ms but60 ms from baseline.Domperidone at the conventionally used doses to treat gastroparesis (30 to 80 mg/d) was associated with QTc prolongation in only 6% of patients with no QT interval reaching the point considered to be clinically significant. These data suggest that domperidone can be safely prescribed at doses of 30 to 80 mg daily for the treatment of gastroparesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|